{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:38:03Z","timestamp":1761183483372,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.dmpk.2015.12.005","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T18:30:05Z","timestamp":1452623405000},"page":"117-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis"],"prefix":"10.1016","volume":"31","author":[{"given":"Sumonrat","family":"Chuwongwattana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thawinee","family":"Jantararoungtong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria N.","family":"Chitasombat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apichaya","family":"Puangpetch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santirat","family":"Prommas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pitchaya","family":"Dilokpattanamongkol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siriorn P.","family":"Watcharananan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2015.12.005_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dmpk.2015.12.005_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkm389","article-title":"Antifungal serum concentration monitoring: an update","volume":"61","author":"Goodwin","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.dmpk.2015.12.005_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","article-title":"Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients","volume":"35","author":"Trifilio","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.dmpk.2015.12.005_bib4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2015.12.005_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1086\/653683","article-title":"Use of intralesional voriconazole for the treatment of cutaneous Scedosporium apiospermum infection","volume":"51","author":"Azofra","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dmpk.2015.12.005_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"year":"2014","series-title":"Vfend prescribing information","author":"Inc","key":"10.1016\/j.dmpk.2015.12.005_bib7"},{"key":"10.1016\/j.dmpk.2015.12.005_bib8","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2006.01548.x","article-title":"Voriconazole prophylaxis in lung transplant recipients","volume":"6","author":"Husain","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dmpk.2015.12.005_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2006.01.018","article-title":"Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis","volume":"55","author":"Siwek","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.dmpk.2015.12.005_bib10","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1128\/AAC.00046-13","article-title":"Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, n-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation","volume":"57","author":"Amsden","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmpk.2015.12.005_bib11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","article-title":"Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17","volume":"69","author":"Li-Wan-Po","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2125.2001.00318.x","article-title":"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil","volume":"51","author":"Hyland","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.bcp.2007.03.012","article-title":"Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes","volume":"73","author":"Murayama","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","article-title":"Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype","volume":"68","author":"Scholz","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00228-010-0869-3","article-title":"Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism","volume":"66","author":"Shi","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dmpk.2015.12.005_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11096-015-0143-y","article-title":"Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians","volume":"37","author":"Chawla","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.dmpk.2015.12.005_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/gim.0b013e3182329870","article-title":"Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory","volume":"14","author":"Strom","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.dmpk.2015.12.005_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2217\/pgs.11.18","article-title":"Pharmacogenomics of the triazole antifungal agent voriconazole","volume":"12","author":"Mikus","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.dmpk.2015.12.005_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2125.2010.03801.x","article-title":"Clinical importance of the CYP2C19*17 variant allele for voriconazole","volume":"71","author":"Dolton","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00228-008-0574-7","article-title":"The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers","volume":"65","author":"Wang","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2009.01.008","article-title":"Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes","volume":"34","author":"Matsumoto","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.dmpk.2015.12.005_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2334-13-105","article-title":"Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events","volume":"13","author":"Chu","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.dmpk.2015.12.005_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dmpk.2015.12.005_bib25","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1097\/MPH.0b013e3182880eaa","article-title":"Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children","volume":"35","author":"Narita","year":"2013","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-010-0914-2","article-title":"Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients","volume":"67","author":"Berge","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.dmpk.2015.12.005_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1086\/524670","article-title":"What is the \u201ctherapeutic range\u201d for voriconazole?","volume":"46","author":"Lewis","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dmpk.2015.12.005_bib29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.dmpk.2015.12.005_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.dmpk.2015.12.005_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1472-8206.2007.00510.x","article-title":"Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population","volume":"21","author":"Arvanitidis","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.12.005_bib33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1439-0507.2012.02186.x","article-title":"Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience","volume":"55","author":"Racil","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.dmpk.2015.12.005_bib34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","article-title":"Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring","volume":"33","author":"Hassan","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2015.12.005_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections","volume":"69","author":"Wang","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436715000841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436715000841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:52:28Z","timestamp":1761162748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1347436715000841"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2015.12.005","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2015.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}